Abstract
We previously demonstrated that the intraperitoneal administration of palmitoylethanolamide (PEA) in mice with chronic constriction injury of the sciatic nerve evoked a relief of both thermal hyperalgesia and mechanical allodynia in neuropathic mice. Since diabetic neuropathy is one of the most common long-term complications of diabetes, we explored the ability of PEA to also relief this kind of chronic pain, employing the well established streptozotocin-induced animal model of type 1 diabetes. Our findings demonstrated that PEA relieves mechanical allodynia, counteracts nerve growth factor deficit, improves insulin level, preserves Langherans islet morphology reducing the development of insulitis in diabetic mice. These results suggest that PEA could be effective in type1 -diabetic patients not only as pain reliever but also in controlling the development of pathology.
Keywords: Allodynia, diabetes, endocannabinoid, insulin, insulitis, mast cell, nerve growth factor, neuropathy, oxidative stress, Palmitoylethanolamide.
CNS & Neurological Disorders - Drug Targets
Title:Palmitoylethanolamide Relieves Pain and Preserves Pancreatic Islet Cells in a Murine Model of Diabetes
Volume: 14 Issue: 4
Author(s): Giulia Donvito, Isabella Bettoni, Francesca Comelli, Anita Colombo and Barbara Costa
Affiliation:
Keywords: Allodynia, diabetes, endocannabinoid, insulin, insulitis, mast cell, nerve growth factor, neuropathy, oxidative stress, Palmitoylethanolamide.
Abstract: We previously demonstrated that the intraperitoneal administration of palmitoylethanolamide (PEA) in mice with chronic constriction injury of the sciatic nerve evoked a relief of both thermal hyperalgesia and mechanical allodynia in neuropathic mice. Since diabetic neuropathy is one of the most common long-term complications of diabetes, we explored the ability of PEA to also relief this kind of chronic pain, employing the well established streptozotocin-induced animal model of type 1 diabetes. Our findings demonstrated that PEA relieves mechanical allodynia, counteracts nerve growth factor deficit, improves insulin level, preserves Langherans islet morphology reducing the development of insulitis in diabetic mice. These results suggest that PEA could be effective in type1 -diabetic patients not only as pain reliever but also in controlling the development of pathology.
Export Options
About this article
Cite this article as:
Donvito Giulia, Bettoni Isabella, Comelli Francesca, Colombo Anita and Costa Barbara, Palmitoylethanolamide Relieves Pain and Preserves Pancreatic Islet Cells in a Murine Model of Diabetes, CNS & Neurological Disorders - Drug Targets 2015; 14 (4) . https://dx.doi.org/10.2174/1871527314666150429111537
DOI https://dx.doi.org/10.2174/1871527314666150429111537 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
TRPM8: From Cold to Cancer, Peppermint to Pain
Current Pharmaceutical Biotechnology From Amino Acids to Proteins as Targets for Metal-based Drugs
Current Drug Metabolism Glaucoma and Aging
Current Aging Science Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets Blood Pressure Variability/Dipper/Non-dipper in Hypertension and Diabetes
Current Hypertension Reviews Role of Vitamins in Neurodegenerative Diseases: A Review
CNS & Neurological Disorders - Drug Targets Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles
Current Drug Safety Role of Azoles in Cancer Prevention and Treatment: Present and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry The Hot and Potential Targets of Type 2 Diabetes Mellitus Treatment in Recent Decade
Current Drug Targets 2015 Update of Erectile Dysfunction Management Following Radical Prostatectomy: From Basic Research to Clinical Management
Current Pharmaceutical Design Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Vasopressin Secretion Control: Central Neural Pathways, Neurotransmitters and Effects of Drugs
Current Pharmaceutical Design Autophagy in Diabetic Retinopathy
Current Neuropharmacology Charcot Neuroarthropathy: From the Laboratory to the Bedside
Current Diabetes Reviews Genetic and Molecular Basis of QTL of Diabetes in Mouse: Genes and Polymorphisms
Current Genomics Patent Annotations
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Cardiovascular Complications in Diabetes: Lessons from Animal Models
Current Medicinal Chemistry Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection
Current Pharmaceutical Design Role of Oxidative Stress in Development of Cardiovascular Complications in Diabetes Mellitus
Current Vascular Pharmacology Melatonin in Antinociception: Its Therapeutic Applications
Current Neuropharmacology